Industries > Pharma > Primary Immunodeficiency Market Report 2021-2031
Primary Immunodeficiency Market Report 2021-2031
By Type (Antibody Deficiency, Cellular Deficiency, and Innate Immune), By Treatment Type (Immunoglobuline replacement Therapy, Antibiotic Therapy, Stem cell and Gene Therapy, and Others), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Leading Regional/ Country market analysis
Primary Immunodeficiency Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Primary Immunodeficiency is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 240+ page report provides 350+ tables and 330+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Primary Immunodeficiency Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Primary Immunodeficiency Market By Type
• Antibody Deficiency
o Agammaglobulinaemia
o Common Variable Immune Deficiency
o Selective IgA Deficiency
o IgG Subclass Deficiency
o Others
• Cellular Deficiency
o Ataxia Telangiectasia
o Hyper IgM Syndromes
o Wiskott-Aldrich Syndrome
o DiGeorge Syndrome
o Others
• Innate Immune
o Complement Deficiencies
o Hyper IgE Syndrome
o Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Primary Immunodeficiency Market By Treatment Type
• Immunoglobuline replacement Therapy
• Antibiotic Therapy
• Stem cell and Gene Therapy
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Primary Immunodeficiency Market By Patient Demographics
• Adults
• Geriatric
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Primary Immunodeficiency Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Primary Immunodeficiency Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Primary Immunodeficiency Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Primary Immunodeficiency Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Primary Immunodeficiency Market report helps you
In summary, our 240+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Primary Immunodeficiency Market, with forecasts for Get our report today Primary Immunodeficiency Market Forecast 2021-2031: By Type, Treatment Type, Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Primary Immunodeficiency market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Primary Immunodeficiency Market. Some of the company’s profiled in this report include
• Baxter International, Inc.
• Shire
• CSL Behring
• Kedrion Biopharma Inc.
• Grifols, S.A.
• Octapharma
• China Biologic Products Holdings, Inc.
• Biotest AG
• Sanquin
• LFB SA
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Primary Immunodeficiency Market and leading companies. You will find data, trends and predictions
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Primary Immunodeficiency Market Report 2021-2031: By Type (Antibody Deficiency, Cellular Deficiency, and Innate Immune), By Treatment Type (Immunoglobuline replacement Therapy, Antibiotic Therapy, Stem cell and Gene Therapy, and Others), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Primary Immunodeficiency Market
2.1. Primary Immunodeficiency Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Primary Immunodeficiency Market Overview
3.1. Global Primary Immunodeficiency Market Size and Forecast By Region
3.2. Global Primary Immunodeficiency Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of Primary Immunodeficiency Disease (PIDD) around the World
3.3.1.2. Availability of Reimbursement in Developing Nations
3.3.1.3. Rapid Surge in the research and development activities
3.3.1.4. Increasing awareness regarding availability of treatment
3.3.2. Market Restraints
3.3.2.1. High cost of product development
3.3.2.2. Stringent regulations
3.3.3. Opportunities
3.3.3.1. Increasing Therapeutic Advancements in Molecular Techniques Open up New Treatment Alternatives for Primary Immunodeficiency Disorders
3.3.3.2. Increasing focus on Healthcare Infrastructure
3.3.4. Challenges
3.3.4.1. Side effects associated with the drug
3.3.4.2. Requirement of high investment for storage
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Primary Immunodeficiency Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Antibody Deficiency
4.1.1.1. Antibody Deficiency market size and forecast, 2021-2031 (USD Million)
4.1.2. Cellular Deficiency
4.1.2.1. Cellular Deficiency market size and forecast, 2021-2031 (USD Million)
4.1.3. Innate Immune
4.1.3.1. Innate Immune market size and forecast, 2021-2031 (USD Million)
5. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By Treatment Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Immunoglobuline replacement Therapy
5.1.1.1. Immunoglobuline replacement Therapy market size and forecast, 2021-2031 (USD Million)
5.1.2. Antibiotic Therapy
5.1.2.1. Antibiotic Therapy market size and forecast, 2021-2031 (USD Million)
5.1.3. Stem cell and Gene Therapy
5.1.3.1. Stem cell and Gene Therapy market size and forecast, 2021-2031 (USD Million)
5.1.4. Others
5.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospitals
7.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
7.1.2. Homecare
7.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
7.1.3. Specialty Clinics
7.1.3.1. Specialty Clinics size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals Pharmacy
8.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.2. Retail Pharmacy
8.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.3. Online Pharmacies
8.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
9. North America Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. North America Primary Immunodeficiency Market Size and Forecast By Type
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. North America Primary Immunodeficiency Market Size and Forecast By Treatment Type
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. North America Primary Immunodeficiency Market Size and Forecast By Patient Demographics
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. North America Primary Immunodeficiency Market Size and Forecast By End-User
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. North America Primary Immunodeficiency Market Size and Forecast By Distribution Channel
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. U.S. Primary Immunodeficiency Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. Canada Primary Immunodeficiency Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
10. Europe Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Europe Primary Immunodeficiency Market Size and Forecast By Type
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Europe Primary Immunodeficiency Market Size and Forecast By Treatment Type
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Europe Primary Immunodeficiency Market Size and Forecast By Patient Demographics
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Europe Primary Immunodeficiency Market Size and Forecast By End-User
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. Europe Primary Immunodeficiency Market Size and Forecast By Distribution Channel
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. UK Primary Immunodeficiency Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Germany Primary Immunodeficiency Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. France Primary Immunodeficiency Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
10.10. Rest of Europe Primary Immunodeficiency Market
10.10.1.1. XX Driving/Opportunity Factor
10.10.1.2. XX Driving/Opportunity Factor
11. Asia Pacific Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Type
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Treatment Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By End-User
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Distribution Channel
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. China Primary Immunodeficiency Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. India Primary Immunodeficiency Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Japan Primary Immunodeficiency Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Rest of Asia Pacific Primary Immunodeficiency Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Latin America Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Latin America Primary Immunodeficiency Market Size and Forecast By Type
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Latin America Primary Immunodeficiency Market Size and Forecast By Treatment Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Latin America Primary Immunodeficiency Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Latin America Primary Immunodeficiency Market Size and Forecast By End-User
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Latin America Primary Immunodeficiency Market Size and Forecast By Distribution Channel
12.7. Brazil Primary Immunodeficiency Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Mexico Primary Immunodeficiency Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. Rest of Latin America Primary Immunodeficiency Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
13. MEA Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. MEA Primary Immunodeficiency Market Size and Forecast By Type
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. MEA Primary Immunodeficiency Market Size and Forecast By Treatment Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. MEA Primary Immunodeficiency Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. MEA Primary Immunodeficiency Market Size and Forecast By End-User
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. MEA Primary Immunodeficiency Market Size and Forecast By Distribution Channel
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. GCC Primary Immunodeficiency Market
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. South Africa Primary Immunodeficiency Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Rest of MEA Primary Immunodeficiency Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
14. Companies in the Primary Immunodeficiency Market
14.1. Baxter International
14.1.1. Company Snapshot
14.1.2. Company Overview
14.1.3. Financial Performance (2015-2019)
14.1.3.1. Net Revenue
14.1.3.2. Gross Profit
14.1.3.3. Geographical Revenue, 2019
14.1.4. Product Offerings
14.1.5. Recent Initiatives (2017-2019)
14.2. Shire
14.2.1. Company Snapshot
14.2.2. Company Overview
14.2.3. Financial Performance (2015-2019)
14.2.3.1. Net Revenue
14.2.3.2. Gross Profit
14.2.3.3. Geographical Revenue, 2019
14.2.4. Product Offerings
14.2.5. Recent Initiatives (2017-2019)
14.3. CSL Behring
14.3.1. Company Snapshot
14.3.2. Company Overview
14.3.3. Financial Performance (2015-2019)
14.3.3.1. Net Revenue
14.3.3.2. Gross Profit
14.3.3.3. Geographical Revenue, 2019
14.3.4. Product Offerings
14.3.5. Recent Initiatives (2017-2019)
14.4. GRIFOLS, S.A
14.4.1. Company Snapshot
14.4.2. Company Overview
14.4.3. Financial Performance (2015-2019)
14.4.3.1. Net Revenue
14.4.3.2. Gross Profit
14.4.3.3. Geographical Revenue, 2019
14.4.4. Product Offerings
14.4.5. Recent Initiatives (2017-2019)
14.5. KEDRION BIOPHARMA INC.
14.5.1. Company Snapshot
14.5.2. Company Overview
14.5.3. Financial Performance (2015-2019)
14.5.3.1. Net Revenue
14.5.3.2. Gross Profit
14.5.3.3. Geographical Revenue, 2019
14.5.4. Product Offerings
14.5.5. Recent Initiatives (2017-2019)
14.6. Octapharma USA, Inc.
14.6.1. Company Snapshot
14.6.2. Company Overview
14.6.3. Financial Performance (2015-2019)
14.6.3.1. Net Revenue
14.6.3.2. Gross Profit
14.6.3.3. Geographical Revenue, 2019
14.6.4. Product Offerings
14.6.5. Recent Initiatives (2017-2019)
14.7. LFB SA
14.7.1. Company Snapshot
14.7.2. Company Overview
14.7.3. Financial Performance (2015-2019)
14.7.3.1. Net Revenue
14.7.3.2. Gross Profit
14.7.3.3. Geographical Revenue, 2019
14.7.4. Product Offerings
14.7.5. Recent Initiatives (2017-2019)
14.8. China Biologics.
14.8.1. Company Snapshot
14.8.2. Company Overview
14.8.3. Financial Performance (2015-2019)
14.8.3.1. Net Revenue
14.8.3.2. Gross Profit
14.8.3.3. Geographical Revenue, 2019
14.8.4. Product Offerings
14.8.5. Recent Initiatives (2017-2019)
14.9. Biotest AG
14.9.1. Company Snapshot
14.9.2. Company Overview
14.9.3. Financial Performance (2015-2019)
14.9.3.1. Net Revenue
14.9.3.2. Gross Profit
14.9.3.3. Geographical Revenue, 2019
14.9.4. Product Offerings
14.9.5. Recent Initiatives (2017-2019)
14.10. Sanquin
14.10.1. Company Snapshot
14.10.2. Company Overview
14.10.3. Financial Performance (2015-2019)
14.10.3.1. Net Revenue
14.10.3.2. Gross Profit
14.10.3.3. Geographical Revenue, 2019
14.10.4. Product Offerings
14.10.5. Recent Initiatives (2017-2019)
14.11. Other Notable Players
15. Conclusion
16. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Primary Immunodeficiency Market Drivers & Restraints 2021
Table 7. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 158. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Leading 10 Primary Immunodeficiency Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 332. Baxter InternationalProfile 2019 (CEO, HQ, Founded, Website)
Table 333. Baxter International Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 334. Shire Profile 2019 (CEO, HQ, Founded, Website)
Table 335. Shire Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 336. CSL Behring Profile 2019 (CEO, HQ, Founded, Website)
Table 337. CSL Behring.Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 338. GRIFOLS, S.A Profile 2019 (CEO, HQ, Founded, Website)
Table 339. GRIFOLS, S.A Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 340. KEDRION BIOPHARMA INC. Profile 2019 (CEO, HQ, Founded, Website)
Table 341. KEDRION BIOPHARMA INC. Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 342. Octapharma USA, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 343. Octapharma USA, Inc. Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 344. LFB SA Profile 2019 (CEO, HQ, Founded, Website)
Table 345. LFB SA Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 346. China Biologics. Profile 2019 (CEO, HQ, Founded, Website)
Table 347. China Biologics. Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 348. Biotest AG Profile 2019 (CEO, HQ, Founded, Website)
Table 349. Biotest AG Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 350. Sanquin Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 351. Sanquin Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 352. Other Companies Involved in the Primary Immunodeficiency Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Primary Immunodeficiency Market Drivers & Restraints 2021
Figure 7. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 118. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 158. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 183. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 184. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 185. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 186. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 187. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 188. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 189. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 190. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 191. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 192. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 193. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 194. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 195. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 196. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 197. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Primary Immunodeficiency Market
2.1. Primary Immunodeficiency Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Primary Immunodeficiency Market Overview
3.1. Global Primary Immunodeficiency Market Size and Forecast By Region
3.2. Global Primary Immunodeficiency Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of Primary Immunodeficiency Disease (PIDD) around the World
3.3.1.2. Availability of Reimbursement in Developing Nations
3.3.1.3. Rapid Surge in the research and development activities
3.3.1.4. Increasing awareness regarding availability of treatment
3.3.2. Market Restraints
3.3.2.1. High cost of product development
3.3.2.2. Stringent regulations
3.3.3. Opportunities
3.3.3.1. Increasing Therapeutic Advancements in Molecular Techniques Open up New Treatment Alternatives for Primary Immunodeficiency Disorders
3.3.3.2. Increasing focus on Healthcare Infrastructure
3.3.4. Challenges
3.3.4.1. Side effects associated with the drug
3.3.4.2. Requirement of high investment for storage
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Primary Immunodeficiency Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Antibody Deficiency
4.1.1.1. Antibody Deficiency market size and forecast, 2021-2031 (USD Million)
4.1.2. Cellular Deficiency
4.1.2.1. Cellular Deficiency market size and forecast, 2021-2031 (USD Million)
4.1.3. Innate Immune
4.1.3.1. Innate Immune market size and forecast, 2021-2031 (USD Million)
5. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By Treatment Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Immunoglobuline replacement Therapy
5.1.1.1. Immunoglobuline replacement Therapy market size and forecast, 2021-2031 (USD Million)
5.1.2. Antibiotic Therapy
5.1.2.1. Antibiotic Therapy market size and forecast, 2021-2031 (USD Million)
5.1.3. Stem cell and Gene Therapy
5.1.3.1. Stem cell and Gene Therapy market size and forecast, 2021-2031 (USD Million)
5.1.4. Others
5.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospitals
7.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
7.1.2. Homecare
7.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
7.1.3. Specialty Clinics
7.1.3.1. Specialty Clinics size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals Pharmacy
8.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.2. Retail Pharmacy
8.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.3. Online Pharmacies
8.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
9. North America Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. North America Primary Immunodeficiency Market Size and Forecast By Type
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. North America Primary Immunodeficiency Market Size and Forecast By Treatment Type
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. North America Primary Immunodeficiency Market Size and Forecast By Patient Demographics
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. North America Primary Immunodeficiency Market Size and Forecast By End-User
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. North America Primary Immunodeficiency Market Size and Forecast By Distribution Channel
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. U.S. Primary Immunodeficiency Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. Canada Primary Immunodeficiency Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
10. Europe Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Europe Primary Immunodeficiency Market Size and Forecast By Type
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Europe Primary Immunodeficiency Market Size and Forecast By Treatment Type
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Europe Primary Immunodeficiency Market Size and Forecast By Patient Demographics
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Europe Primary Immunodeficiency Market Size and Forecast By End-User
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. Europe Primary Immunodeficiency Market Size and Forecast By Distribution Channel
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. UK Primary Immunodeficiency Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Germany Primary Immunodeficiency Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. France Primary Immunodeficiency Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
10.10. Rest of Europe Primary Immunodeficiency Market
10.10.1.1. XX Driving/Opportunity Factor
10.10.1.2. XX Driving/Opportunity Factor
11. Asia Pacific Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Type
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Treatment Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By End-User
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Asia-Pacific Primary Immunodeficiency Market Size and Forecast By Distribution Channel
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. China Primary Immunodeficiency Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. India Primary Immunodeficiency Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Japan Primary Immunodeficiency Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Rest of Asia Pacific Primary Immunodeficiency Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Latin America Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Latin America Primary Immunodeficiency Market Size and Forecast By Type
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Latin America Primary Immunodeficiency Market Size and Forecast By Treatment Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Latin America Primary Immunodeficiency Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Latin America Primary Immunodeficiency Market Size and Forecast By End-User
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Latin America Primary Immunodeficiency Market Size and Forecast By Distribution Channel
12.7. Brazil Primary Immunodeficiency Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Mexico Primary Immunodeficiency Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. Rest of Latin America Primary Immunodeficiency Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
13. MEA Primary Immunodeficiency Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. MEA Primary Immunodeficiency Market Size and Forecast By Type
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. MEA Primary Immunodeficiency Market Size and Forecast By Treatment Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. MEA Primary Immunodeficiency Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. MEA Primary Immunodeficiency Market Size and Forecast By End-User
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. MEA Primary Immunodeficiency Market Size and Forecast By Distribution Channel
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. GCC Primary Immunodeficiency Market
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. South Africa Primary Immunodeficiency Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Rest of MEA Primary Immunodeficiency Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
14. Companies in the Primary Immunodeficiency Market
14.1. Baxter International
14.1.1. Company Snapshot
14.1.2. Company Overview
14.1.3. Financial Performance (2015-2019)
14.1.3.1. Net Revenue
14.1.3.2. Gross Profit
14.1.3.3. Geographical Revenue, 2019
14.1.4. Product Offerings
14.1.5. Recent Initiatives (2017-2019)
14.2. Shire
14.2.1. Company Snapshot
14.2.2. Company Overview
14.2.3. Financial Performance (2015-2019)
14.2.3.1. Net Revenue
14.2.3.2. Gross Profit
14.2.3.3. Geographical Revenue, 2019
14.2.4. Product Offerings
14.2.5. Recent Initiatives (2017-2019)
14.3. CSL Behring
14.3.1. Company Snapshot
14.3.2. Company Overview
14.3.3. Financial Performance (2015-2019)
14.3.3.1. Net Revenue
14.3.3.2. Gross Profit
14.3.3.3. Geographical Revenue, 2019
14.3.4. Product Offerings
14.3.5. Recent Initiatives (2017-2019)
14.4. GRIFOLS, S.A
14.4.1. Company Snapshot
14.4.2. Company Overview
14.4.3. Financial Performance (2015-2019)
14.4.3.1. Net Revenue
14.4.3.2. Gross Profit
14.4.3.3. Geographical Revenue, 2019
14.4.4. Product Offerings
14.4.5. Recent Initiatives (2017-2019)
14.5. KEDRION BIOPHARMA INC.
14.5.1. Company Snapshot
14.5.2. Company Overview
14.5.3. Financial Performance (2015-2019)
14.5.3.1. Net Revenue
14.5.3.2. Gross Profit
14.5.3.3. Geographical Revenue, 2019
14.5.4. Product Offerings
14.5.5. Recent Initiatives (2017-2019)
14.6. Octapharma USA, Inc.
14.6.1. Company Snapshot
14.6.2. Company Overview
14.6.3. Financial Performance (2015-2019)
14.6.3.1. Net Revenue
14.6.3.2. Gross Profit
14.6.3.3. Geographical Revenue, 2019
14.6.4. Product Offerings
14.6.5. Recent Initiatives (2017-2019)
14.7. LFB SA
14.7.1. Company Snapshot
14.7.2. Company Overview
14.7.3. Financial Performance (2015-2019)
14.7.3.1. Net Revenue
14.7.3.2. Gross Profit
14.7.3.3. Geographical Revenue, 2019
14.7.4. Product Offerings
14.7.5. Recent Initiatives (2017-2019)
14.8. China Biologics.
14.8.1. Company Snapshot
14.8.2. Company Overview
14.8.3. Financial Performance (2015-2019)
14.8.3.1. Net Revenue
14.8.3.2. Gross Profit
14.8.3.3. Geographical Revenue, 2019
14.8.4. Product Offerings
14.8.5. Recent Initiatives (2017-2019)
14.9. Biotest AG
14.9.1. Company Snapshot
14.9.2. Company Overview
14.9.3. Financial Performance (2015-2019)
14.9.3.1. Net Revenue
14.9.3.2. Gross Profit
14.9.3.3. Geographical Revenue, 2019
14.9.4. Product Offerings
14.9.5. Recent Initiatives (2017-2019)
14.10. Sanquin
14.10.1. Company Snapshot
14.10.2. Company Overview
14.10.3. Financial Performance (2015-2019)
14.10.3.1. Net Revenue
14.10.3.2. Gross Profit
14.10.3.3. Geographical Revenue, 2019
14.10.4. Product Offerings
14.10.5. Recent Initiatives (2017-2019)
14.11. Other Notable Players
15. Conclusion
16. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Primary Immunodeficiency Market Drivers & Restraints 2021
Table 7. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 158. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Leading 10 Primary Immunodeficiency Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 332. Baxter InternationalProfile 2019 (CEO, HQ, Founded, Website)
Table 333. Baxter International Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 334. Shire Profile 2019 (CEO, HQ, Founded, Website)
Table 335. Shire Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 336. CSL Behring Profile 2019 (CEO, HQ, Founded, Website)
Table 337. CSL Behring.Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 338. GRIFOLS, S.A Profile 2019 (CEO, HQ, Founded, Website)
Table 339. GRIFOLS, S.A Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 340. KEDRION BIOPHARMA INC. Profile 2019 (CEO, HQ, Founded, Website)
Table 341. KEDRION BIOPHARMA INC. Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 342. Octapharma USA, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 343. Octapharma USA, Inc. Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 344. LFB SA Profile 2019 (CEO, HQ, Founded, Website)
Table 345. LFB SA Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 346. China Biologics. Profile 2019 (CEO, HQ, Founded, Website)
Table 347. China Biologics. Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 348. Biotest AG Profile 2019 (CEO, HQ, Founded, Website)
Table 349. Biotest AG Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 350. Sanquin Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 351. Sanquin Primary Immunodeficiency Product Offering (Segment, Product Offerings)
Table 352. Other Companies Involved in the Primary Immunodeficiency Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Primary Immunodeficiency Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Primary Immunodeficiency Market Drivers & Restraints 2021
Figure 7. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Antibody Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Cellular Deficiency Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Innate Immune Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Immunoglobuline replacement Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Antibiotic Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Stem cell and Gene Therapy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 118. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. North America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. North America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. North America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. North America Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. US Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Canada Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 158. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Europe Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Europe Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Europe Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Europe Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Europe Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 183. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 184. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 185. Europe Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 186. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 187. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 188. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 189. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 190. UK Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 191. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 192. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 193. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 194. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 195. Germany Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 196. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 197. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. France Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. Rest of Europe Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Asia Pacific Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. Asia Pacific Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Asia Pacific Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Asia Pacific Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Asia Pacific Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Asia Pacific Primary Immunodeficiency Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. China Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. India Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Japan Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. RoAPAC Primary Immunodeficiency Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Middle East Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Middle East Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Middle East Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Middle East Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Middle East Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Latin America Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Latin America Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Latin America Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Latin America Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Latin America Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Africa Primary Immunodeficiency Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Africa Primary Immunodeficiency Market Forecast By Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Africa Primary Immunodeficiency Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Africa Primary Immunodeficiency Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Africa Primary Immunodeficiency Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
Companies Profiled in the Report
1. Baxter International, Inc.
2. Shire
3. CSL Behring
4. Kedrion Biopharma Inc.
5. Grifols, S.A.
6. Octapharma
7. China Biologic Products Holdings, Inc.
8. Biotest AG
9. Sanquin
10. LFB SA
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
1. Baxter International, Inc.
2. Shire
3. CSL Behring
4. Kedrion Biopharma Inc.
5. Grifols, S.A.
6. Octapharma
7. China Biologic Products Holdings, Inc.
8. Biotest AG
9. Sanquin
10. LFB SA
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
Download sample pages
Complete the form below to download your free sample pages for Primary Immunodeficiency Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Primary Immunodeficiency Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
